INSMED INC Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
INSMED INC (INSM) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-02-19
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was $0.00.
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-06-30 was $0.00.
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-03-31 was $0.00.
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $0.00.
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00.
- INSMED INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2011 was $19.70M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-02-20 | |||
| 2011-12-31 | $19.70M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |